We are delighted to announce that the audiovisual summary of the CRYSTAL3 project (Commercial & Research Opportunity for Cysteinyl Leukotriene Signaling in Ocular & CNS Dysfunction, Cancer and Cardiovascular Disease) has been published on YouTube.

The CRYSTAL3 project started in January 2021 and came to an end in December 2024. The international consortium was led by University College Dublin (UCD) has secured EU Horizon 2020 funding valued at €887,800 to investigate a specific cell signalling process seen across a range of human diseases.

The CRYSTAL3 consortium included 15 partners (7 academic and 8 industry) located in 9 countries and were be led by Professor Breandán Kennedy from UCD School of Biomolecular and Biomedical Science and UCD Conway Institute. The project focused on commercial and research opportunities of a relatively unexplored inflammation-related signalling pathway. Central to this pathway are powerful molecules called cysteinyl leukotrienes (CysLTs) that are involved in the process of inflammation – the body’s response to fight injury or pathogens. CysLT signalling receptors are found widely in the body e.g. lungs, colorectum, heart, brain & eye.The CRYSTAL3 consortium combined their resources and expertise in computational drug discovery, genetic engineering, pre-clinical disease models, marketing and commercialisation through research staff exchanges between all the partners.

The academic partners were University College Dublin; Trinity College Dublin; Linköping University, Sweden; International Iberian Nanotechnology Laboratory, Portugal; University of Göttingen, Germany; Andalusian Public Foundation Progress and Health, Spain and Comenius University Bratislava, Slovakia with industry partners Ocupharm, Spain; Xenopat, Spain; Bioreperia, Sweden; Cresset, United Kingdom; Experimentica, Finland; De Rotos y Descosidos, Spain; Mursla, United Kingdom and Pharmahungary, Hungary.